07.10.2013 • NewsBiogenBiogen IdecMS treatment

Biogen's New MS Drug Maintains Efficacy Long Term -Study

Biogen Idec's hot-selling new multiple sclerosis drug Tecfidera remained effective for patients taking the medicine for at least four years with no new safety problems, according to interim data from a long-term study. Tecfidera, which analysts expect to eventually dominate the MS market, had sales of $192 million in its first quarter on the market - nearly triple average Wall Street expectations. The Endorse extension study followed patients who had taken part in two pivotal Phase III trials that led to the U.S. approval of Tecfidera.

 

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read